gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Neuropeptide Y receptor Y5

Y5 receptor, NPY5R
Top mentioned proteins: Neuropeptide, neuropeptide Y, V1a, HAD, CAN
Papers on Y5 receptor
Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine.
Gil-Ad et al., Tel Aviv-Yafo, Israel. In J Mol Neurosci, Dec 2015
A significant increase in hypothalamic protein expression of the neuropeptide Y5 receptor and a decrease in pro-opiomelanocortin messenger ribonucleic acid (mRNA) levels were detected following PGW5 treatment, but not after olanzapine administration.
Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE-/- knockout mice fed normal diet.
Gu et al., Wuhan, China. In Atherosclerosis, Nov 2015
Moreover, mRNA expressions of NPY1R, NPY2R and NPY5R in aortic and myocardial tissue were also significantly upregulated in M4 and M8 groups.
Neuropeptide Y family receptors Y1 and Y2 from sea lamprey, Petromyzon marinus.
Larhammar et al., Uppsala, Sweden. In Gen Comp Endocrinol, Nov 2015
However, previously only a Y4-like and a Y5 receptor have been cloned and characterized.
NPY-Y1 coexpressed with NPY-Y5 receptors modulate anxiety but not mild social stress response in mice.
Eva et al., Cagliari, Italy. In Genes Brain Behav, Sep 2015
We previously demonstrated that conditional removal of the Y1 receptor in the Y5 receptor expressing neurons in juvenile Npy1r(Y5R-/-) mice leads to higher anxiety but no changes in hypothalamus-pituitary-adrenocortical axis activity, under basal conditions or after acute restraint stress.
Activation of Neuropeptide Y Receptors Modulates Retinal Ganglion Cell Physiology and Exerts Neuroprotective Actions In Vitro.
Ambrósio et al., Coimbra, Portugal. In Asn Neuro, Jul 2015
Moreover, (Leu31, Pro34)-NPY, a Y1/Y5 receptor agonist, increased the initial burst response of OFF-type RGCs, although no effect was observed on RGC spontaneous spiking activity.
New and emerging drug molecules against obesity.
Shanmugam et al., Kānchipuram, India. In J Cardiovasc Pharmacol Ther, 2014
Tesofensine is a triple monoamine re-uptake inhibitor, velneperit acts as a neuropeptide Y5 receptor antagonist and beloranib is a methionine amino peptidase 2 inhibitor.
Leung, Bethesda, United States. In Unknown Journal, 2012
The Y2 and Y4 receptor subtypes are thought to inhibit appetite, whereas the Y1 and Y5 receptor subtypes are responsible for stimulation of appetite.
Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line.
Amlal et al., Cincinnati, United States. In Mol Cancer Res, 2010
Together, our results suggest that Y5R plays an important role in cancer cell growth and migration and could be a novel therapeutic target for breast cancer.
Modulation of neuropeptide Y receptors for the treatment of obesity.
Ando et al., Saitama, Japan. In Expert Opin Ther Pat, 2009
A number of synthetic ligands for NPY receptor subtypes have been developed to date, with Y5 receptor antagonists and Y2 and Y4 receptor agonists advancing into clinical trials.
Cloning and characterization of rabbit neuropeptide Y receptor subtypes.
Iwaasa et al., Tsukuba, Japan. In Peptides, 2009
Results suggest that rabbit and human Y1, Y2 and Y5 receptor subtypes are well conserved, whereas Y4 receptors are less well conserved.
Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence.
Foroud et al., Indianapolis, United States. In Alcohol Clin Exp Res, 2008
Sequence variations in neuropeptide Y receptor genes (NPY5R and NPY2R) are associated with alcohol dependence, cocaine dependence, and comorbid alcohol and cocaine dependence.
Variants in neuropeptide Y receptor 1 and 5 are associated with nutrient-specific food intake and are under recent selection in Europeans.
Onland-Moret et al., Utrecht, Netherlands. In Plos One, 2008
NPY1R and NPY5R have roles in nutrient-specific food intake in Europeans
Association of neuropeptide Y receptor Y5 polymorphisms with dyslipidemia in Mexican Americans.
Jenkinson et al., San Antonio, United States. In Obesity (silver Spring), 2007
single nucleotide polymorphisms in the NPY5R gene may have a role in dyslipidemia (elevated triglyceride concentrations and reduced high-density lipoprotein levels) in Mexican Americans
NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs.
MacNeil, Rahway, United States. In Curr Top Med Chem, 2006
A combination of pharmacological and genetic studies in mice confirmed that the Y1 and Y5 receptors mediate the potent orexigenic actions of exogenous NPY.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Heymsfield et al., Rahway, United States. In Cell Metab, 2006
We tested the hypothesis that blockade of the NPY5R will lead to weight loss in humans using MK-0557, a potent, highly selective, orally active NPY5R antagonist.
Treating obesity: does antagonism of NPY fit the bill?
Farooqi, Cambridge, United Kingdom. In Cell Metab, 2006
In this issue of Cell Metabolism, Erondu et al., (2006) identify a selective neuropeptide Y5 receptor antagonist that, as predicted from rodent studies, results in weight loss when administered to overweight and obese human subjects.
Design and synthesis of (ant)-agonists that alter appetite and adiposity.
Guan et al., Boston, United States. In Prog Brain Res, 2005
In this review, we will discuss drug development efforts for the treatment of obesity, focused on selective melanocortin 4 receptor agonists and neuropeptide Y1 and Y5 receptor antagonists.
Role of the Y5 neuropeptide Y receptor in feeding and obesity.
Palmiter et al., Seattle, United States. In Nat Med, 1998
Pharmacological data suggest that NPY's stimulatory effect on appetite is transduced by the G-protein-coupled NPY Y5 receptor (Y5R).
Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors.
Bolwig et al., Copenhagen, Denmark. In Nat Med, 1997
This effect was mediated via receptors with a pharmacological profile similar to the recently cloned rat Y5 receptor.
A receptor subtype involved in neuropeptide-Y-induced food intake.
Weinshank et al., Paramus, United States. In Nature, 1996
The extent to which selected peptides can inhibit adenylate cyclase through the Y5 receptor and stimulate food intake in rats correspond well.
share on facebooktweetadd +1mail to friends